JP6800842B2 - プリドピジンの類似体、それらの製造および使用 - Google Patents

プリドピジンの類似体、それらの製造および使用 Download PDF

Info

Publication number
JP6800842B2
JP6800842B2 JP2017520772A JP2017520772A JP6800842B2 JP 6800842 B2 JP6800842 B2 JP 6800842B2 JP 2017520772 A JP2017520772 A JP 2017520772A JP 2017520772 A JP2017520772 A JP 2017520772A JP 6800842 B2 JP6800842 B2 JP 6800842B2
Authority
JP
Japan
Prior art keywords
compound
predopidine
phenyl
bis
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017520772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519839A (ja
JP2017519839A5 (cg-RX-API-DMAC7.html
Inventor
シュミット、マーレ
ペリ、マーレ
ラオス、マリット
マッサル、アンツ
カルユステ、カレ
Original Assignee
プリレニア ニューロセラピューティクス リミテッド
プリレニア ニューロセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリレニア ニューロセラピューティクス リミテッド, プリレニア ニューロセラピューティクス リミテッド filed Critical プリレニア ニューロセラピューティクス リミテッド
Publication of JP2017519839A publication Critical patent/JP2017519839A/ja
Publication of JP2017519839A5 publication Critical patent/JP2017519839A5/ja
Application granted granted Critical
Publication of JP6800842B2 publication Critical patent/JP6800842B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Spectroscopy & Molecular Physics (AREA)
JP2017520772A 2014-06-30 2015-06-29 プリドピジンの類似体、それらの製造および使用 Active JP6800842B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462019337P 2014-06-30 2014-06-30
US62/019,337 2014-06-30
US201462076436P 2014-11-06 2014-11-06
US62/076,436 2014-11-06
PCT/US2015/038349 WO2016003919A1 (en) 2014-06-30 2015-06-29 Analogs of pridopidine, their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020077160A Division JP7035108B2 (ja) 2014-06-30 2020-04-24 プリドピジンの類似体、それらの製造および使用

Publications (3)

Publication Number Publication Date
JP2017519839A JP2017519839A (ja) 2017-07-20
JP2017519839A5 JP2017519839A5 (cg-RX-API-DMAC7.html) 2018-08-09
JP6800842B2 true JP6800842B2 (ja) 2020-12-16

Family

ID=54929343

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017520772A Active JP6800842B2 (ja) 2014-06-30 2015-06-29 プリドピジンの類似体、それらの製造および使用
JP2020077160A Active JP7035108B2 (ja) 2014-06-30 2020-04-24 プリドピジンの類似体、それらの製造および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020077160A Active JP7035108B2 (ja) 2014-06-30 2020-04-24 プリドピジンの類似体、それらの製造および使用

Country Status (17)

Country Link
US (4) US10130621B2 (cg-RX-API-DMAC7.html)
EP (2) EP4049998A1 (cg-RX-API-DMAC7.html)
JP (2) JP6800842B2 (cg-RX-API-DMAC7.html)
CN (2) CN113511997A (cg-RX-API-DMAC7.html)
AU (1) AU2015284385B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016030968B1 (cg-RX-API-DMAC7.html)
CA (1) CA2951494C (cg-RX-API-DMAC7.html)
DK (1) DK3160470T3 (cg-RX-API-DMAC7.html)
EA (1) EA201790101A1 (cg-RX-API-DMAC7.html)
ES (1) ES2927888T3 (cg-RX-API-DMAC7.html)
HU (1) HUE060242T2 (cg-RX-API-DMAC7.html)
IL (2) IL249601B (cg-RX-API-DMAC7.html)
MX (1) MX382649B (cg-RX-API-DMAC7.html)
PL (1) PL3160470T3 (cg-RX-API-DMAC7.html)
TW (1) TW201613859A (cg-RX-API-DMAC7.html)
UY (1) UY36192A (cg-RX-API-DMAC7.html)
WO (1) WO2016003919A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
SMT202600016T1 (it) * 2019-06-12 2026-03-09 Prilenia Neurotherapeutics Ltd Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi
EP4741013A3 (en) * 2020-02-13 2026-08-05 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的s1rアゴニストを使用するウイルス感染、疾患、又は障害の治療
AU2021366505A1 (en) * 2020-10-20 2023-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine and analogs for the treatment of anxiety and depression
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
CA3214354A1 (en) * 2021-04-14 2022-10-20 Michael Hayden Treatment of prodromal huntington disease
WO2023062632A1 (en) * 2021-10-11 2023-04-20 Prilenia Neurotherapeutics Ltd. Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
CN114716391B (zh) * 2022-04-24 2023-12-12 杭州仟源保灵药业有限公司 一种醋甲唑胺杂质及其制备方法和应用
CA3250337A1 (en) 2022-05-03 2023-11-09 Prilenia Neurotherapeutics Ltd. METHODS AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE
CN118924710B (zh) * 2024-08-05 2026-06-19 成都新睿志远生物医药股份有限公司 细辛脑在制备治疗和/或预防眼部疾病药物中的应用和一种组合物及其应用
WO2026035949A1 (en) * 2024-08-08 2026-02-12 Prilenia Therapeutics Inc. Combination of pridopidine and low dose anti-dopaminergic medication (adm) for treating huntington disease and sympto thereof
WO2026080658A1 (en) 2024-10-10 2026-04-16 Prilenia Therapeutics Inc. Pridopidine for the treatment of distal hereditary motor neuropathy (dhmn)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6472736A (en) 1987-09-14 1989-03-17 Toshiba Corp Mri apparatus
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
JP2008501748A (ja) * 2004-06-08 2008-01-24 ニューロサーチ スウェーデン アクチボラゲット ドーパミン神経伝達のモジュレーターとしての新規な置換されたピペリジン
US7629461B2 (en) * 2004-09-04 2009-12-08 Teva Pharmaceutical Industries Ltd Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
ES2659577T3 (es) * 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
MX2007004216A (es) * 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
JP2007526342A (ja) * 2005-01-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 低レベルの不純物を有するオルメサルタンメドキソミル
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
MX2009011020A (es) * 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20150209346A1 (en) * 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
IL311081A (en) * 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline

Also Published As

Publication number Publication date
DK3160470T3 (da) 2022-10-24
CN113511997A (zh) 2021-10-19
US11141412B2 (en) 2021-10-12
US10406145B2 (en) 2019-09-10
AU2015284385B2 (en) 2021-01-21
US20220023280A1 (en) 2022-01-27
PL3160470T3 (pl) 2022-11-21
EP3160470A4 (en) 2018-01-10
CA2951494C (en) 2023-10-03
US20190030016A1 (en) 2019-01-31
US20150374677A1 (en) 2015-12-31
IL272306B (en) 2021-04-29
IL249601A0 (en) 2017-02-28
US10130621B2 (en) 2018-11-20
EP3160470B1 (en) 2022-08-03
CN106456618A (zh) 2017-02-22
EA201790101A1 (ru) 2017-06-30
WO2016003919A1 (en) 2016-01-07
HK1231406A1 (en) 2017-12-22
WO2016003919A8 (en) 2017-01-26
ES2927888T3 (es) 2022-11-11
BR112016030968A2 (pt) 2018-07-17
EP4049998A1 (en) 2022-08-31
MX382649B (es) 2025-03-13
UY36192A (es) 2016-01-29
BR112016030968B1 (pt) 2023-11-21
JP7035108B2 (ja) 2022-03-14
JP2020143072A (ja) 2020-09-10
AU2015284385A1 (en) 2017-02-02
IL249601B (en) 2020-01-30
MX2016017332A (es) 2017-05-12
IL272306A (en) 2020-03-31
JP2017519839A (ja) 2017-07-20
TW201613859A (en) 2016-04-16
US20200030308A1 (en) 2020-01-30
HUE060242T2 (hu) 2023-02-28
EP3160470A1 (en) 2017-05-03
CA2951494A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
JP7035108B2 (ja) プリドピジンの類似体、それらの製造および使用
US10047117B2 (en) Preparation and uses of obeticholic acid
EP4130000A1 (en) Spiro ring-containing quinazoline compound
HUE030547T2 (en) Aryl dihydropyridinones and piperidinones as MGAT2 inhibitors
WO2019169156A1 (en) Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
WO2023060173A1 (en) Compounds, compositions and methods of use
KR20150022816A (ko) N-에틸-4-하이드록실-1-메틸-5-(메틸(2,3,4,5,6-펜타하이드록시헥실)아미노)-2-옥소-n-페닐-1,2-디하이드로퀴놀린-3-카복스아미드
RS67052B1 (sr) Vmat2 inhibitori i postupci primene
KR20260054707A (ko) Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 응용
EP2851363A1 (en) Agomelatine acid radical composite, and preparation method and application thereof
EP4741391A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
CN110804026B (zh) 1- (3- (3-(4-氯苯基)丙氧基)丙基)哌啶盐酸盐的合成方法
RU2603770C2 (ru) Замещенные пиразинопиримидиноны как блокаторы trpa1 каналов, фармацевтическая композиция, способы их получения и применения
HK40078313A (en) Analogs of pridopidine, their preparation and use
EP4582086A2 (en) Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same
EA041145B1 (ru) Фармацевтические композиции, содержащие производные придопидина, их применение для лечения пациента, страдающего нейродегенеративным заболеванием или нейродегенеративным расстройством
HK1233503A1 (en) Analogs of pridopidine, their preparation and use
HK1231406B (en) Analogs of pridopidine, their preparation and use
EA051207B1 (ru) Пиридилсодержащее соединение
WO2025185643A1 (zh) 用作cdk4蛋白激酶抑制剂的化合物及其应用
CN121627661A (zh) 一类2-硫-3-(哌啶烷二硫基)苯酞及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191119

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200918

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200925

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201125

R150 Certificate of patent or registration of utility model

Ref document number: 6800842

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250